GSK Hails Success For Novel Antibiotic – But Reaching $1bn Sales Will Be A Challenge
Company Expects To File In H1 2023
GSK is returning to its long heritage in antibiotics with a potential first-in-class drug that has just shown promise in urinary tract infection; hopes are that it can reach annual sales of $1bn.
You may also be interested in...
Despite recording the first success for an adjuvant drug therapy in hepatocellular carcinoma, Roche is likely to need longer-term safety and efficacy data before attempting a filing.
The pharma licensed global rights to Scynexis’s Brexafemme, a first-in-class triterpenoid antifungal approved for treat and prevent recurrence of vaginal yeast infections, for $90m up front.
Results from a Phase II trial have demonstrated the potential of GSK's first-in-class antitubercular agent to be a component of simpler treatment regimens for tuberculosis in the future.